Your AI-Trained Oncology Knowledge Connection!
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.
Patricia M. LoRusso, DO, widely-regarded as a leading expert on developing new cancer drugs through clinical trials, will join Yale Cancer Center in August as a Professor of Medicine and Associate Director of Innovative Medicine at Yale Cancer Center.
Improved imaging modalities are needed to help advance treatment of men diagnosed with metastatic prostate cancer, and several novel techniques are under study
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer
Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, gives an overview of the recent changes to the field of genetic testing.
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses novel imaging modalities in prostate cancer.
Thomas J. Lynch, MD, Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology), director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses advances in molecular profiling in lung cancer.
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the using immunotherapy agents to treat patients with lung cancer.
Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the unique benefit of targeting the PD-1/PD-L1 pathway in lung cancer.
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the changes and challenges of treating patients with melanoma.
Roy S. Herbst, MD, PhD, discusses the sequencing possibilities of anti-PD-1 agents in treating patients with lung cancer.
Vincent T. DeVita, Jr, MD, Lymphoma: Giant of Cancer Care, Yale Cancer Center, discusses the use of chemotherapy for patients with Hodgkin's lymphoma.
Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the differences of targeting PD-1 and PD-L1 when treating patients with lung cancer.
Roy S. Herbst, MD, PhD, chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.
Thomas J. Lynch, Jr., MD, from the Yale Cancer Center, pioneered the use of molecular testing for EGFR mutations in lung cancer. In July 2013, he was honored by OncLive as one of the "Giants of Cancer Care."
Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.
The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.
Roy S. Herbst, MD, PhD, from the Yale Cancer Center, discusses determining the eligibility of patients with non-small cell lung cancer for molecular testing.
With increasing use of neoadjuvant chemotherapy in early-stage breast cancer, controversy has erupted regarding the optimal timing of sentinel lymph node biopsy.
While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.
Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.
Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.
Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer
Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.
Dr. Roy S. Herbst from Yale Comprehensive Cancer Center on Themes From the 2011 Lung Cancer Congress
Dr. Roy S. Herbst from Yale comprehensive cancer center on the International Lung Cancer Congress
Dr. Roy Herbst from the Yale Comprehensive Cancer Center on Screening Studies at the Upcoming Lung Cancer Congress